6.12: Primary Health Care, Self-Care, & Harm Minimisation

Primary Health Care, Self-Care, & Harm Minimisation

Pharmacists in Australia play a critical role in primary health care as the most accessible healthcare professionals. Key competencies include understanding the scheduling of medicines, managing minor ailments, providing self-care advice, and delivering harm minimisation services.

Medicine Scheduling in Australia

The scheduling of medicines in Australia is governed by the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP), implemented through state and territory legislation.

---

High-Risk Pharmacist-Only (S3) Protocols

1. Pseudoephedrine Sales

Pseudoephedrine is a highly effective nasal decongestant but is a precursor for the illicit manufacture of methamphetamine. The pharmacist must personally conduct the sale, verify the patient's identity (using photo ID, e.g., driver's license), and record the transaction in the national database (Project STOP). The pharmacist must assess clinical appropriateness (avoid in patients with uncontrolled hypertension, cardiovascular disease, hyperthyroidism, prostatic hypertrophy, or those taking monoamine oxidase inhibitors (MAOIs)).

2. Emergency Hormonal Contraception (EHC)

Two oral options are available as S3 medicines:

• Levonorgestrel (LNG) 1.5 mg (e.g., Postinor-1):
  • Must be taken within 72 hours (3 days) of unprotected sexual intercourse (UPSI).
  • Mechanism: Prevents or delays ovulation by suppressing the luteinising hormone (LH) surge.
  • Drug Interaction: Enzyme-inducing drugs (e.g., carbamazepine, phenytoin, rifampicin, St John's wort) decrease LNG efficacy. For patients taking these, a double dose of LNG (3 mg) is recommended, or a copper intrauterine device (IUD) should be offered.
• Ulipristal Acetate (UPA) 30 mg (e.g., EllaOne):
  • Can be taken up to 120 hours (5 days) after UPSI.
  • Mechanism: Progesterone receptor modulator. It prevents or delays ovulation even after the LH surge has started to rise (unlike LNG, which is ineffective at this stage).
  • Clinical Trap: Do not use progestogen-containing regular contraceptives (e.g., the pill, mini-pill, implants) within 5 days after taking UPA, as they can reduce UPA's efficacy by competing for progesterone receptors. If regular contraception is restarted, barrier methods must be used for 14 days (or 9 days for the mini-pill).

---

Minor Ailments Management & Red Flags

1. Cough & Cold

• Pediatric Restriction: Under Australian guidelines, over-the-counter cough and cold medicines (antitussives, expectorants, decongestants, antihistamines) are contraindicated in children under 6 years of age due to lack of efficacy and risk of harm (e.g., seizures, tachycardia, respiratory depression). They are not recommended for children aged 6–11 years unless advised by a doctor.
• Topical Decongestants (e.g., Oxymetazoline): Must be restricted to a maximum of 3 to 5 consecutive days. Prolonged use causes down-regulation of alpha-adrenergic receptors, leading to rebound nasal congestion (rhinitis medicamentosa).

2. Gastrointestinal Disorders

• Acute Diarrhoea: First-line therapy is always fluid and electrolyte replacement using Oral Rehydration Salts (ORS). Antimotility agents (e.g., loperamide) can be used as adjuncts in adults but are contraindicated in children and in patients with suspected bacterial dysentery (characterised by high fever and bloody/mucoid stools) or Clostridioides difficile infection.
• Reflux & Dyspepsia: Antacids provide rapid but short-lived relief. H2-receptor antagonists (e.g., famotidine) and PPIs (e.g., esomeprazole 20 mg, pantoprazole 20 mg) are available over-the-counter (S3) for short-term (up to 14 days) treatment of frequent heartburn.
• Red Flags (Require GP Referral): Dysphagia (difficulty swallowing), odynophagia (painful swallowing), unexplained weight loss, persistent vomiting, hematemesis, melaena, or symptoms failing to respond to 2 weeks of PPI therapy.

---

Smoking Cessation Strategies

The pharmacist's role in smoking cessation is structured around the 5 A's framework: Ask, Assess, Advise, Assist, Arrange.

1. Nicotine Replacement Therapy (NRT):
   • Available as patches, gums, lozenges, inhalators, and mouth sprays.
   • Combination NRT: Combining a long-acting nicotine patch (provides steady baseline levels) with a fast-acting oral NRT (e.g., gum or mouth spray for breakthrough cravings) is clinically proven to be significantly more effective than monotherapy.
   • Formulation selection: 24-hour patches are preferred for patients who experience morning cravings, but if vivid dreams or sleep disturbances occur, the patch should be removed at bedtime (or switched to a 16-hour patch).
2. Prescription-Only (S4) Pharmacotherapy:
   • Varenicline: A selective nicotinic acetylcholine receptor partial agonist. It relieves craving and withdrawal symptoms while blocking the rewarding effects of smoking. Patients must be monitored for neuropsychiatric symptoms (e.g., depression, suicidal ideation).
   • Bupropion: A norepinephrine-dopamine reuptake inhibitor. Contraindicated in patients with a history of seizures or eating disorders.

---

Harm Minimisation Programs

Harm minimisation is a key public health strategy in Australia consisting of three pillars: demand reduction, supply reduction, and harm reduction.

1. Needle and Syringe Programs (NSP): Community pharmacies participate by supplying sterile injecting equipment and safe disposal containers (sharps bins). This program significantly reduces the transmission of blood-borne viruses (HIV, Hepatitis B, and Hepatitis C) among people who inject drugs.
2. Opioid Substitution Therapy (OST) / Opioid Pharmacotherapy Program: Pharmacists dispense opioid substitutes to registered patients under strict clinical guidelines:
   • Methadone: A full mu-opioid receptor agonist with a long half-life. High risk of accumulation and QTc prolongation.
   • Buprenorphine: A partial mu-opioid receptor agonist (available as sublingual films, often combined with naloxone to prevent intravenous misuse, or as weekly/monthly depot injections). It has a ceiling effect on respiratory depression, making it safer in overdose.
   • Dispensing Protocols:
     • Intoxication Check: Before dosing, the pharmacist must check for signs of intoxication (e.g., slurred speech, unsteady gait, pinpoint pupils, drowsiness). If intoxication is suspected, the dose must be withheld, and the prescriber notified immediately. Dosing an intoxicated patient carries a high risk of fatal respiratory depression.
     • Takeaway Doses: Takeaway doses are strictly regulated to prevent diversion and accidental overdose. Pharmacists must supply takeaways in child-resistant containers with appropriate labeling.